James Peace
Retina Specialist · Inglewood, CANPI 1497836423
Payments from drug & device makers
Across 408 payments — averaging $1400.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$245K
- Kala Pharmaceuticals, Inc.$66K
- Ocular Therapeutix, Inc.$60K
- Novartis$47K
- Bausch & Lomb Americas Inc.$46K
- Padagis US LLC$43K
- plus $65K from 27 others
Across 1 payment — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$14,65719%
- Speaking & faculty fees$41,48054%
- Travel & lodging$6,0498%
- Food & beverage$14,32719%
- Entertainment$3250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $245,123 |
| Kala Pharmaceuticals, Inc. | 16 | $65,940 |
| Ocular Therapeutix, Inc. | 12 | $59,871 |
| Novartis | 24 | $47,269 |
| Bausch & Lomb Americas Inc. | 91 | $45,834 |
| Padagis US LLC | 2 | $42,650 |
| Bausch Health US, LLC | 4 | $28,690 |
| Thea Pharma Inc. | 23 | $12,318 |
| Oyster Point Pharma, Inc. | 5 | $7,098 |
| Aerie Pharmaceuticals, Inc. | 26 | $7,094 |
| Perrigo Company PLC | 3 | $5,425 |
| Sun Pharmaceutical Industries Inc. | 31 | $1,219 |
| Alcon | 27 | $816 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $490 |
| Optos, Inc. | 5 | $325 |
| Mallinckrodt Hospital Products Inc. | 8 | $294 |
| Astellas Pharma Global Development | 1 | $146 |
| Amgen(2 entities) | 6 | $139 |
| NEW World Medical,inc. | 1 | $129 |
| Kowa Research Institute, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $86 |
| Shire North American Group Inc | 3 | $80 |
| Rxsight Inc | 3 | $69 |
| Glaukos Corporation | 1 | $55 |
| Harrow Eye, LLC | 2 | $54 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $47 |
| LKC Technologies, Inc. | 1 | $43 |
| Carl Zeiss Meditec, Inc. | 1 | $33 |
| Dompe US, Inc. | 1 | $22 |
| Sight Sciences, Inc. | 1 | $21 |
| Akorn, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$43,063
- XIIDRA$26,541
- IYUZEH$10,173
- Rocklatan$6,470
- Rhopressa$6,360
- EYSUVIS$2,978
- LOTEMAX SM$433
- VYZULTA$372
- CEQUA$367
- enVista MX60 IOL$265
- STELLARIS ELITE$265
- P200DTx$204
- P200T$204
- P200TE$204
- P200TxE$204
- ACTHAR$150
- Izervay$146
- TRYPTYR$145
- XIPERE$142
- SURGICAL MISC$141
How this compares
$571,554 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 831 | $259,121 |
| RestasisCyclosporine | 151 | $135,348 |
| XiidraLifitegrast | 117 | $115,754 |
| Cyclosporine | 223 | $89,250 |
| CombiganBrimonidine Tartrate/Timolol | 286 | $70,013 |
| ProlensaBromfenac Sodium | 180 | $62,161 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 460 | $45,800 |
| MieboPerfluorohexyloctane/Pf | 51 | $43,493 |
| Bromfenac Sodium | 169 | $38,266 |
| RhopressaNetarsudil Mesylate | 104 | $34,921 |
| Alphagan PBrimonidine Tartrate | 109 | $30,719 |
| Brimonidine Tartrate | 638 | $28,266 |
| Restasis MultidoseCyclosporine | 33 | $20,336 |
| BesivanceBesifloxacin Hcl | 55 | $12,974 |
| Brinzolamide | 84 | $12,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P, Restasis Multidose | $245,123 | $515,5381,410 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $45,834 | $159,247168 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate | $490 | $77,719247 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $7,094 | $44,566129 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $65,940 | $5,40211 claims |
| AlconSimbrinza | $816 | $4,18721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 retina specialist providers in California.
Other retina specialist in Inglewood
- Dante PieramiciSanta Barbara$15.1M
- Margaret ChangSacramento$13.2M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Joel PearlmanSacramento$8.3M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
- Sean AdreanFullerton$2.9M
- Nathan SteinleSanta Barbara$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.